A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.

Moss, Neil; Choi, Younggi; Cogan, Derek; Flegg, Adam; Kahrs, Andreas; Loke, Pui; Meyn, Orietta; Nagaraja, Raj; Napier, Spencer; Parker, Ashley; Thomas Peterson, J; Ramsden, Philip; Sarko, Christopher; Skow, Donna; Tomlinson, Josh; Tye, Heather; Whitaker, Mark

Moss, Neil; Choi, Younggi; Cogan, Derek; Flegg, Adam; Kahrs, Andreas; Loke, Pui; Meyn, Orietta; Nagaraja, Raj; Napier, Spencer; Parker, Ashley; Thomas Peterson, J; Ramsden, Philip; Sarko, Christopher; Skow, Donna; Tomlinson, Josh; Tye, Heather; Whitaker, Mark.

Affiliation

Moss N; Department of Medicinal Chemistry, Cardiovascular Disease, or Drug Discovery Support, Boehringer Ingelheim Pharmaceutical, Inc, Ridgefield, CT 06877, United States. nmoss@rdg.boehringer-ingelheim.com

Bioorg Med Chem Lett ; 19(8): 2206-10, 2009 Apr 15.

Article in En | MEDLINE | ID: mdl-19307114

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Serotonin Antagonists / Receptor, Serotonin, 5-HT2B / Serotonin 5-HT2 Receptor Antagonists Limits: Animals Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2009 Document type: Article Affiliation country: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google